Obexelimab
- Generic Name
- Obexelimab
- Drug Type
- Biotech
- CAS Number
- 1690307-05-1
- Unique Ingredient Identifier
- RM16A4BA8R
- Background
Obexelimab is under investigation in clinical trial NCT02725515 (A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus).
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 93
- Registration Number
- NCT06564311
- Locations
- 🇺🇸
North Central Neurology, Cullman, Alabama, United States
🇨🇿General University Hospital Praha, Praha, Czechia
🇩🇰Aalborg Universitetshospital, Aalborg, Denmark
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 190
- Registration Number
- NCT06559163
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
🇺🇸Penn State - Hershey Medical Center, Hershey, Pennsylvania, United States
🇧🇪CHU de Liege, Liege, Belgium
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
- Conditions
- Warm Autoimmune Hemolytic Anemia
- Interventions
- Other: Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 134
- Registration Number
- NCT05786573
- Locations
- 🇮🇹
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
🇵🇱Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Pomorskie, Poland
🇪🇸Hospital Universitario de Burgos, Burgos, Spain
A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease
- Conditions
- IgG4 Related Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Zenas BioPharma (USA), LLC
- Target Recruit Count
- 194
- Registration Number
- NCT05662241
- Locations
- 🇦🇷
Consultora Integral de Salud Centro Médico Privado, Córdoba, Argentina
🇨🇦Artus Health Centre, Vancouver, British Columbia, Canada
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
XmAb5871 Bioavailability Study
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02867098
- Locations
- 🇺🇸
PAREXEL, Early Phase Clinical Unit-Los Angeles, Glendale, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.